These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 34368227)

  • 21. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer.
    Wang J; Tan Z; Huang Y; Li C; Zhan P; Wang H; Li H
    Aging (Albany NY); 2024 Jul; 16(14):11385-11408. PubMed ID: 39033778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer.
    Song Z; Gui S; Xiao S; Rao X; Cong N; Deng H; Yu Z; Zeng T
    Sci Rep; 2024 Feb; 14(1):3198. PubMed ID: 38332160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer.
    Sun J; Yue W; You J; Wei X; Huang Y; Ling Z; Hou J
    Front Oncol; 2021; 11():730716. PubMed ID: 34557413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and Development of Inflammatory Response-Related Genes Signature Associated With Prognosis Evaluation and Immune Status of Bladder Cancer.
    Zheng H; Luo W; Li Y; Peng G; Zhou D; Tang D; Cheng J; Wu S
    Front Cell Dev Biol; 2022; 10():837849. PubMed ID: 35309900
    [No Abstract]   [Full Text] [Related]  

  • 27. ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment.
    Pan W; Liu X; Liu S
    Medicine (Baltimore); 2024 Apr; 103(14):e37590. PubMed ID: 38579085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
    Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Ferroptosis-Related Gene Model for Overall Survival Predictions of Bladder Urothelial Carcinoma Patients.
    Zhang M; Zhang X; Yu M; Zhang W; Zhang D; Zeng S; Wang X; Hu X
    Front Oncol; 2021; 11():698856. PubMed ID: 34386423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer.
    Chen X; Jin Y; Gong L; He D; Cheng Y; Xiao M; Zhu Y; Wang Z; Cao K
    Front Genet; 2020; 11():607. PubMed ID: 32655621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of cuproptosis-related long non-coding RNA and construction of a novel prognostic signature for bladder cancer: An observational study.
    Ye Z; Liu C; Wu S; Jin X; Lin H; Wang T; Zheng Q; Guo Z
    Medicine (Baltimore); 2024 May; 103(18):e38005. PubMed ID: 38701267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer.
    Wang D; Ning H; Wu H; Song Y; Chu Y; Liu F; Zhao Z; Wu F; Lyu J
    Curr Urol; 2023 Dec; 17(4):236-245. PubMed ID: 37994343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
    Xu Q; Xu H; Chen S; Huang W
    Front Cell Dev Biol; 2021; 9():710207. PubMed ID: 34409040
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    Li Y; Xu K; Zhang Y; Mao H; Qiu Q; Yan Z; Liu X; Du Y; Chen Z
    BMC Cancer; 2023 Oct; 23(1):1021. PubMed ID: 37872487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
    Gao W; Zhang J; Tian T; Fu Z; Bai L; Yang Y; Wu Q; Wang W; Guo Y
    PeerJ; 2023; 11():e15284. PubMed ID: 37123010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia.
    Hua J; Ding T; Shao Y
    Front Immunol; 2022; 13():1040661. PubMed ID: 36591215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
    Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B
    PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
    BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.